East Shines Over West? US Rejection Puts Roxadustat's China Approval In New Spotlight
Japan, EU Offer Other Growth Alternatives?
Touted in China after its first approval globally there for chronic kidney disease-associated anemia back in late 2018, FibroGen/AstraZeneca's roxadustat has now been rejected by the US FDA over cardiovascular safety concerns. But ex-US markets may still enable the drug to shine despite safety wording.
